SCHEMBL2546761

SCHEMBL2546761

CCCCCc1cccc(C=CC(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 1/20 0.56
▸ MEF2D Q14814 1/20 0.56
▸ KDM4E B2RXH2 3/20 0.55
▸ ALDH1A1 P00352 3/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ NPC1 O15118 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ CASP3 P42574 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ SENP8 Q96LD8 1/20 0.54
▸ SENP7 Q9BQF6 1/20 0.54
▸ SENP6 Q9GZR1 1/20 0.54
▸ LTB4R Q15722 1/20 0.53
▸ LTB4R2 Q9NPC1 1/20 0.53
▸ ATG4B Q9Y4P1 10/20 0.52
▸ PLA2G1B P04054 8/20 0.52
▸ PKM P14618 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.51
▸ THRA P10827 1/20 0.51
▸ THRB P10828 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2546760 1.00 HDAC4 (0.56) HDAC4MEF2DKDM4EALDH1A1SMN1; SMN2
SCHEMBL28366799 0.85 PPARA (0.55) HDAC4MEF2D
SCHEMBL28366800 0.85 PPARA (0.55) HDAC4MEF2D
SCHEMBL28464691 0.84 AKR1C3 (0.49) HDAC4MEF2DKDM4EALDH1A1SMN1; SMN2
SCHEMBL28089990 0.84 HDAC4 (0.58) HDAC4MEF2DKDM4EALDH1A1SMN1; SMN2
SCHEMBL28089992 0.84 HDAC4 (0.58) HDAC4MEF2DKDM4EALDH1A1SMN1; SMN2
SCHEMBL7537284 0.83 LPL (0.51) HDAC4MEF2D
SCHEMBL7539419 0.83 LPL (0.51) HDAC4MEF2D
SCHEMBL846032 0.83 ALDH1A1 (0.69) KDM4EALDH1A1SMN1; SMN2NPC1HPGD
SCHEMBL7539412 0.83 LPL (0.51) HDAC4MEF2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044236-B2 Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-10-25 — — US disclosed
EP-2080751-A1 CARBOXYLIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-07-22 — — EP disclosed
US-20080275116-A1 Carboxilic acid derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275116-A1 Carboxilic acid derivatives SERPINE1, CTRL, SERPINC1 HDAC4 1565/4885MEF2D 4210/4885KDM4E 4508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback